Apixaban: Difference between revisions
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
(Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links) |
||
| Line 61: | Line 61: | ||
|format=broadtable | |format=broadtable | ||
|headers=plain | |headers=plain | ||
| | |mainlabel=- | ||
|sort=Has Indication | |sort=Has Indication | ||
|limit=50 | |limit=50 | ||
Revision as of 17:25, 20 March 2026
Administration
- Type: Anticoagulant
- Dosage Forms: tablet
- Dosage Strengths: 2.5mg, 5mg
- Routes of Administration: Oral
- Common Trade Names: Eliquis
Adult Dosing
Pulmonary embolism, DVT
- 10mg PO twice daily x 7 days, then 5mg BID
Stroke prevention in afib
- 5mg PO BID. Reduce the dose to 2.5 mg PO BID if patient has any 2 of the following: Age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL.
Post-op DVT prophylaxis after hip or knee arthroplasty
- 2.5mg BID
Pediatric Dosing
Safety/efficacy not established
Special Populations
- Pregnancy Rating: B
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: No adjustment for DVT/PE treatment. Afib: 2.5mg BID if creatinine >1.5
- Hepatic dosing: No adjustment for mild impairment. Not recommended if severe impairment.
- Decrease dose if concomitant use of CYP3A4 and P-gp efflux dual inhibitors
Contraindications
- Allergy to class/drug
- Active bleeding
Adverse Reactions
Serious
- Major bleeding (GI, muscular, epidural, intracranial, conjunctival, urinary, intraoperative)
- LFT abnormalities
Common
- Easy bruising, hematoma, gingival bleeding, menorrhagia, epistaxis
Pharmacology
- Half-life: 7-16 hours
- Metabolism: Hepatic, mainly CYP3A4
- Excretion: 25% in urine and feces as metabolites; renal excretion accounts for 27%T of total clearance; biliary and direct intestinal excretion contributes to elimination in feces
Mechanism of Action
- Reversible factor Xa inhibitor→ decreased thrombin synthesis
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Atrial fibrillation (main) | 5 mg BID (reduced: 2.5 mg BID if ≥2 of: age ≥80, wt ≤60 kg, Cr ≥1.5) | Anticoagulation (NOAC) | PO | Adult |
| Pulmonary embolism | 10 mg PO BID x1 week, then 5 mg PO BID | Anticoagulation (DOAC) | PO | Adult |
See Also
- Andexanet alfa
- Anticoagulant reversal for life-threatening bleeds
- Procedures in patients with coagulopathies
- PE
- DVT